Virpax Pharmaceuticals announces results of Probudur dose escalation studies

Virpax Pharmaceuticals announced results for two pre-clinical Probudur dose escalation studies. The first study compared Probudur to Exparel utilizing a planar incision model. Two doses of Probudur, at 3 mg and 6 mg, were administered to rats. The results demonstrated three times longer efficacy for Probudur than Exparel. In the second study, two different formulations at the same dose of Probudur were compared to Exparel in rat incision models. In this study, Probudur demonstrated a four to five times longer effect than the comparable product. “These IND enabling studies confirmed our results from earlier studies,” commented Anthony P. Mack, Chairman and CEO of Virpax Pharmaceuticals. “We only have a few additional studies to be performed and are on track to begin first-in-human trials of Probudur in 2024.” Additional confirmational studies for efficacy, toxicity, and pharmacokinetics are ongoing with others planned in order for the Company to file an Investigational New Drug Application.